PDCD1 and cancer: Furthermore, the distinct mechanisms of action of PD-1 and CTLA-4 pathway blockade, along with the observed synergistic anti-tumor effects of combined treatment in preclinical models (37–39), led to the clinical evaluation of these two ICIs for cancer patients, demonstrating an enhanced clinical response (40).